In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The closing price of Xeris Biopharma Holdings Inc (NASDAQ: XERS) was $7.71 for the day, down -21.88% from the previous closing price of $9.87. In other words, the price has decreased by -$21.88 from its previous closing price. On the day, 10.58 million shares were traded. XERS stock price reached its highest trading level at $8.9485 during the session, while it also had its lowest trading level at $7.0.
Ratios:
Our analysis of XERS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.24 and its Current Ratio is at 1.95.
On November 11, 2024, Piper Sandler Downgraded its rating to Neutral which previously was Overweight but kept the price unchanged to $3.
On March 28, 2024, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $5.Oppenheimer initiated its Outperform rating on March 28, 2024, with a $5 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 11 ’25 when PERSKY MARLA sold 15,500 shares for $7.72 per share. The transaction valued at 119,610 led to the insider holds 142,000 shares of the business.
MARLA PERSKY bought 15,500 shares of XERS for $121,055 on Sep 11 ’25. On Aug 28 ’25, another insider, SHERMAN JEFFREY W, who serves as the Director of the company, sold 42,232 shares for $7.92 each. As a result, the insider received 334,515 and left with 219,188 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XERS now has a Market Capitalization of 1245013632 and an Enterprise Value of 1791749248. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.06. Its current Enterprise Value per Revenue stands at 7.283 whereas that against EBITDA is 213.787.
Stock Price History:
The Beta on a monthly basis for XERS is 0.64, which has changed by 1.8443804 over the last 52 weeks, in comparison to a change of 0.13355756 over the same period for the S&P500. Over the past 52 weeks, XERS has reached a high of $10.08, while it has fallen to a 52-week low of $2.82. The 50-Day Moving Average of the stock is -8.22%, while the 200-Day Moving Average is calculated to be 34.35%.
Shares Statistics:
XERS traded an average of 2.52M shares per day over the past three months and 2117470 shares per day over the past ten days. A total of 161.22M shares are outstanding, with a floating share count of 151.50M. Insiders hold about 6.18% of the company’s shares, while institutions hold 56.67% stake in the company. Shares short for XERS as of 1760486400 were 17850615 with a Short Ratio of 7.07, compared to 1757894400 on 16240329. Therefore, it implies a Short% of Shares Outstanding of 17850615 and a Short% of Float of 11.5.
Earnings Estimates
. The current rating of Xeris Biopharma Holdings Inc (XERS) is the result of assessments by 2.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is $0.03, with high estimates of $0.03 and low estimates of $0.03.
Analysts are recommending an EPS of between -$0.01 and -$0.06 for the fiscal current year, implying an average EPS of -$0.04. EPS for the following year is $0.25, with 2.0 analysts recommending between $0.31 and $0.2.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 4 analysts. It ranges from a high estimate of $83.1M to a low estimate of $81M. As of. The current estimate, Xeris Biopharma Holdings Inc’s year-ago sales were $60.1MFor the next quarter, 4 analysts are estimating revenue of $83.23M. There is a high estimate of $86.9M for the next quarter, whereas the lowest estimate is $80.1M.
A total of 5 analysts have provided revenue estimates for XERS’s current fiscal year. The highest revenue estimate was $288.6M, while the lowest revenue estimate was $286.8M, resulting in an average revenue estimate of $287.68M. In the same quarter a year ago, actual revenue was $203.07MBased on 6 analysts’ estimates, the company’s revenue will be $364M in the next fiscal year. The high estimate is $432.3M and the low estimate is $332.6M.
